Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,524.04 22.39 0.14%
S&P 500 1,880.47 5.08 0.27%
NASDAQ 4,155.62 28.65 0.69%
Ticker Volume Price Price Delta
STOXX 50 3,189.81 13.84 0.44%
FTSE 100 6,703.00 28.26 0.42%
DAX 9,548.68 4.49 0.05%
Ticker Volume Price Price Delta
NIKKEI 14,404.99 -141.28 -0.97%
TOPIX 1,164.90 -8.91 -0.76%
HANG SENG 22,562.80 53.16 0.24%

Sucampo Pharmaceuticals Announces Third Quarter and Nine-Month 2012 Financial Results and Operating Highlights Teleconference



  Sucampo Pharmaceuticals Announces Third Quarter and Nine-Month 2012
  Financial Results and Operating Highlights Teleconference and Webcast

Business Wire

BETHESDA, Md. -- November 01, 2012

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), a global pharmaceutical company,
today announced that it will host a webcast and teleconference with senior
management to discuss its financial results and operating highlights for the
second quarter and nine-month periods ended September 30, 2012, on Thursday,
November 8, 2012, at 5:00 pm Eastern. The press release announcing the
financial results and operating highlights is expected to be released after
the close of the capital markets that day.

Investors interested in accessing the live audio webcast of the teleconference
may do so at
http://investor.sucampo.com/phoenix.zhtml?c=201197&p=irol-calendar and should
log on 10 to 15 minutes before the teleconference begins in order to download
any software required. A replay of the webcast will also be available on the
Company’s website for several days after the live event. Alternatively,
investors may dial 866-788-0545 (domestic) or 1-857-350-1683 (international)
and use passcode 34887168. A replay of the teleconference will be available by
dialing 888-286-8010 (domestic) or 1-617-801-6888 passcode 21448920,
approximately two hours after the teleconference concludes. The archive of the
teleconference will remain available for 30 days.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc., a global pharmaceutical company, is focused on
innovative research, discovery, development and commercialization of
proprietary drugs based on prostones. The therapeutic potential of prostones,
which occur naturally in the human body as a result of enzymic (15-PGDH)
transformation of certain fatty acids, was first identified by Ryuji Ueno,
M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals’ Chairman and Chief Executive
Officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno,
Ph.D., founding Chief Executive Officer. For more information, please visit
www.sucampo.com.

Sucampo Forward-Looking Statements

This press release contains “forward-looking statements” as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements are based on management’s current expectations and involve risks
and uncertainties, which may cause results to differ materially from those set
forth in the statements. The forward-looking statements may include statements
regarding product development, product potential, future financial and
operating results, and other statements that are not historical facts. The
following factors, among others, could cause actual results to differ from
those set forth in the forward-looking statements: the impact of
pharmaceutical industry regulation and health care legislation; Sucampo’s
ability to accurately predict future market conditions; dependence on the
effectiveness of Sucampo’s patents and other protections for innovative
products; the risk of new and changing regulation and health policies in the
US and internationally and the exposure to litigation and/or regulatory
actions.

No forward-looking statement can be guaranteed and actual results may differ
materially from those projected. Sucampo undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new information,
future events, or otherwise. Forward-looking statements in this presentation
should be evaluated together with the many uncertainties that affect Sucampo’s
business, particularly those mentioned in the risk factors and cautionary
statements in Sucampo’s Form 10-K for the year ended Dec. 31, 2011, which the
Company incorporates by reference.

Contact:

Sucampo Pharmaceuticals, Inc.
Silvia Taylor, +1-240-223-3718
staylor@sucampo.com
or
Kate de Santis, +1-240-223-3834
kdesantis@sucampo.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement